
浏览全部资源
扫码关注微信
1.210093 南京,南京大学医学院
2.210009 南京,东南大学临床医学院
3.210029 南京,南京中医药大学附属医院/江苏省中医院核医学科
4.210002 南京,南京大学医学院附属金陵医院/南京军区南京总医院医学影像科
[杜明华,E-mail: njdmh@aliyun.comDU Minghua, E-mail: njdmh@aliyun.com
收稿:2017-09-30,
修回:2017-12-07,
纸质出版:2018-03-15
移动端阅览
季发权, 戚宁, 张东升, 等. 131I-antiAFP导向载药纳米粒对肝癌移植瘤的抑制作用[J]. 第三军医大学学报, 2018,40(5):395-399.
Faquan JI, Ning QI, Dongsheng ZHANG, et al. Inhibitory effect 131I-antiAFP McAb-DOX-BSA nanoparticles on hepatocellular carcinoma bearing nude mice[J]. Journal of Third Military Medical University, 2018, 40(5): 395-399.
季发权, 戚宁, 张东升, 等. 131I-antiAFP导向载药纳米粒对肝癌移植瘤的抑制作用[J]. 第三军医大学学报, 2018,40(5):395-399. DOI: 10.16016/j.1000-5404.201709228.
Faquan JI, Ning QI, Dongsheng ZHANG, et al. Inhibitory effect 131I-antiAFP McAb-DOX-BSA nanoparticles on hepatocellular carcinoma bearing nude mice[J]. Journal of Third Military Medical University, 2018, 40(5): 395-399. DOI: 10.16016/j.1000-5404.201709228.
目的
2
探讨
131
I-antiAFP McAb-DOX-BSA-NP对肝癌移植瘤的抑制和杀伤作用。
方法
2
制备
131
I-antiAFP McAb-DOX-BSA-NP;培养人肝癌细胞株BEL-7402及建立荷瘤裸鼠模型;将成瘤裸鼠模型按随机数字表法分为5组,每组6只。A组:空白对照组(生理盐水);B组:单纯
131
I核素治疗组;C组:
131
I-antiAFP McAb治疗组;D组:
131
I-antiAFP McAb-DOX-BSA-NP治疗组;E组:antiAFP McAb-DOX-BSA-NP治疗组。裸鼠瘤周注射治疗,DOX剂量为40 μg/只,
131
I活度0.2 mCi/只(1 mCi=3.7×10
7
Bq),注射体积为0.2 mL/只。于4、9、14、20 d测量并记录各组裸鼠瘤体体积。同时分别在24、48、96、168 h对放射治疗组(B、C、D组)裸鼠进行SPECT检查。
结果
2
标记产物呈澄清溶液;pH值7.4;放射性化学纯度
>
99%,活度浓度3.91 mCi/mL;在0.2 mol/L PB缓冲液中1、2、4 h放射性化学纯度分别为97.17%、97.10%、95.22%,稳定性良好。各组裸鼠治疗后肿瘤体积变化及生长抑制率比较:B、C、D、E治疗组较空白对照组肿瘤体积明显减小(
P
<
0.05);与B、C、E
组比较,D组肿瘤生长抑制率最强,差异有统计学意义(
P
<
0.05)。SPECT检查结果显示:24 h时,B、C、D 3组瘤区放射性计数值差异无统计学意义(
P
>
0.05);48、96、168 h时,
131
I-antiAFP McAb-DOX-BSA-NP治疗组(D组)及
131
I-antiAFP McAb治疗组(C组)放射性计数值均高于
131
I治疗组(B组),差异均具有统计学意义(
P
<
0.05),且随时间延长其差异性越来越显著。
结论
2
单克隆抗体免疫治疗、放射性
131
I内照射治疗及载药纳米粒缓释化疗联合运用对肝癌移植瘤有显著抗癌效果。
Objective
2
To determine the anti-tumor effect of
131
I-antiAFP monoclonal antibody-doxorubicin-bovine serum albumin nanoparticles (
131
I-antiAFP McAb-DOX-BSA-NP) on hepatocarcinoma bearing nude mice.
Methods
2
The antiAFP McAb-DOX-BSA-NP were prepared and then labelled with radio-iodine. Tumor xenograft model was established by transplanting human hepatoma BEL-7402 cells in nude mice. Then the model mice were randomly divided into 5 groups
that is
blank control group (group A
normal saline)
131
I treatment group (group B)
131
I-antiAFP McAb treatment group (group C)
131
I-antiAFP McAb-DOX-BSA-NP treatment group (group D)
and antiAFP McAb-DOX-BSA-NP treatment group (group E)
with 6 mice in each group. The agents were injected around the tumor mass
with per animal receiving DOX 40 μg and
131
I 0.2 mCi in a total volume of 0.2 mL. The tumor volume was measured in 4
9
14 and 20 d. The nude mice in groups B
C and D treated with radionuclide were examined with SPECT in 24
48
96 and 196 h for radioactive counting.
Results
2
The labeled product presented as clear solution
with a pH value of 7.4
radioactive chemical purity of
>
99%
and activity of 3.91 mCi/mL. The radioactive chemical purity became 97.17%
97.10% and 95.22% in 1
2 and 4 h respectively
when in the 0.2 mol/L PB buffer
which indicating good stability of the prepared nanoparticles. The tumor size was significant
ly smaller in the groups B
C
D and E than the group A (
P
<
0.05). The tumor growth rate was most strongly suppressed in the group D
with obvious differences when compared with those in groups B
C and E (
P
<
0.05). SPECT indicated that there was no statistical difference in the radioactive count in groups B
C and D in 24 h (
P
>
0.05)
but the counts in 48
96 and 168 h were notably higher in the groups D and C than the group B (
P
<
0.05)
and the differences were more significant over time.
Conclusion
2
Our prepared nanoparticles show significant anti-tumor effect for hepatocellular carcinoma bearing nude mice.
GBOLAHAN O B, SCHACHT M A, BECKLEY E W, et al . Locoregional and systemic therapy for hepatocellular carcinoma[J ] . J Gastrointest Oncol, 2017, 8(2): 215-228. DOI: 10.21037/jgo.2017.03.13.
BEST J, SCHOTTEN C, THEYSOHN J M, et al . Novel implications in the treatment of hepatocellular carcinoma[J ] . Ann Gastroenterol, 2017, 30(1): 23-32. DOI: 10.20524/aog.2016.0092.
宋晓斌, 李晨玉, 方晓白, 等.探讨键合表阿霉素纳米胶束对肝癌Walker-256细胞周期的影响[J].中国实验诊断学, 2017, 21(2): 313-315. DOI: 1007-4287(2017)02-0313-03.
SONG X B, LI C Y, FANG X B, et al . Effect on key BHB adriamycin nano micelle Walker-256 hepatumor cells cycle[J ] . Chin J Lab Diagn, 2017, 21(2): 313-315. DOI: 1007-4287(2017)02-0313-03.
LIN M, HUANG J, ZHANG D, et al . Hepatoma-targeted radionuclide immune albumin nanospheres: 131 I-antiAFPMcAb-GCV-BSA-NPs[J ] . Anal Cell Pathol (Amst), 2016, 2016: 9142198. DOI: 10.1155/2016/9142198..
LI W, LIU Z, LI C, et al . Radionuclide therapy using 131 I-labeled anti-epidermal growth factor receptor-targeted nano-particles suppresses cancer cell growth caused by EGFR over-expression[J ] . J Cancer Res Clin Oncol, 2016, 142(3): 619-632. DOI:10.1007/s00432-015-2067-2..
戚宁, 杜明华, 张东生, 等.制备单抗偶联载阿霉素白蛋白免疫毫微球的初步研究[J].东南大学学报(医学版), 2012, 31(4): 393-397. DOI: 10.3969/j.issn.1671-6264.2012.04.002.
QI Ning, DU Minghua, ZHANG Dongsheng, et al . Preliminary study on preparation of doxorubicin-loaded bovine serum albumin targeted at antiAFP immuno-nanoparticle[J ] . J Southeast Univ (Med Sci Edi), 2012, 31(4): 393-397. DOI: 10.3969/j.issn.1671-6264.2012.04.002.issn. 1671-6264.2012.04.002.
LI J, ZHOU M, LIU F, et al . Hepatocellular carcinoma: intra-arterial delivery of doxorubicin-loaded hollow gold nanospheres for photothermal ablation-chemoembolization therapy in rats[J ] . Radiology, 2016, 281(2): 427-435. DOI:10.1148/radiol.2016152510.
QIN J M, YIN P H, LI Q, et al . Anti-tumor effects of brucine immuno-nanoparticles on hepatocellular carcinoma[J ] . Int J Nanomedicine, 2012, 7: 369-379. DOI:10.2147/IJN.S27226.
DANGI R, HURKAT P, JAIN A, et al . Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles[J ] . J Microencapsul, 2014, 31(5): 479-487. DOI: 10.3109/02652048.2013.879929..
谢志君, 李立, 尤真明, 等.基于人体有效半减期计算 131 I投入量对治疗Graves'甲亢转归的影响[J ] .第三军医大学学报, 2017, 39(21): 2131-2134. DOI: 10.16016/j.1000-5404.201706068.
XIE Z J, LI L, YOU Z M, et al . Impact of 131 I given dose based on individual effective half-life on Graces disease outcome: a clinical study of 201 cases[J ] . J Third Mil Med Univ, 2017, 39(21): 2131-2134. DOI: 10.16016/j.1000-5404.201706068..
CHI J L, LI C C, XIA C Q, et al . Effect of 131 I gelatin microspheres on hepatocellular carcinoma in nude mice and its distribution after intratumoral injection[J ] . Radiat Res, 2014, 181(4): 416-424. DOI: 10.1667/RR13539.1..
李佳. 不可切除的大肠癌肝转移多学科综合治疗进展(附3例病例讨论)[D]. 汕头: 汕头大学, 2011. [http://cdmd.cnki.com.cn/Article/CDMD-10560-1011206792.htm .
LI J. Advances in multidisciplinary synthetic therapy for unresectable liver metastasis of colorectal cancer (Three cases discussion)[D]. Shantou: Shantou University, 2011.
赵文思, 周寒静, 罗弋. ABCG2特异性肺腺癌单链抗体的裸鼠体内放免显像及其抑瘤作用[J].第三军医大学学报, 2016, 38(24):2600-2605. DOI: 10.16016/j.1000-5404.201606125.
ZHAO W S, ZHOU H J, LUO Y. Radioimmunoimaging and anti-tumor effect of anti-ABCG2 single-chain antibody in nude mice with lung adenocarcinoma transplantation[J]. J Third Mil Med Univ, 2016, 38(24):2600-2605. DOI: 10.16016/j.1000-5404.201606125.
殷香保, 邬林泉, 黄长文, 等.阿霉素纳米-VEGFR2单抗交联物的抗肝癌作用[J].广东医学, 2014, 35(19):2972-2975. DOI:10.13820/j.cnki.gdyx.2014.19.002.
YIN X B, WU L Q, HUANG C W, et al . The effect of adriamycin nanoparticles-VEGFR2 monoclonal antibody on hepatic carcinoma[J ] . Guangdong Med J, 2014, 35(19):2972-2975. DOI:10.13820/j.cnki.gdyx.2014.19.002.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621